|1.||Grandmaison, Gaël: 1 article (06/2013)|
|2.||dos Santos, Isis: 1 article (06/2013)|
|3.||Santos, Alba: 1 article (06/2013)|
|4.||Le Roy, Didier: 1 article (06/2013)|
|5.||Ciarlo, Eleonora: 1 article (06/2013)|
|6.||Roger, Thierry: 1 article (06/2013)|
|7.||Lugrin, Jérôme: 1 article (06/2013)|
|8.||Fahrner, René: 1 article (04/2013)|
|9.||Keogh, Adrian: 1 article (04/2013)|
|10.||Tschan, Mario P: 1 article (04/2013)|
06/01/2013 - "Cambinol was originally described as a compound inhibiting the activity of SIRT1 and SIRT2, with efficient anti-tumor activity in vivo. "
04/01/2013 - "In an orthotopic xenograft model, knockdown of SIRT1 resulted in 50% fewer animals developing tumors and cambinol treatment resulted in an overall lower tumor burden. "
06/01/2012 - "In the in vivo model, the efficacy of doxorubicin itself (88% reduction in tumor volume) again overshadowed any effect of cotreatment with vorinostat or cambinol on the WT tumors. "
06/01/2012 - "However, in the DoxR tumors, doxorubicin alone had no efficacy, but cotreatment with either cambinol or vorinostat suppressed tumor growth (70% and 91% reduction in tumor volume, respectively). "
|3.||Septic Shock (Toxic Shock Syndrome)
06/01/2013 - "The sirtuin inhibitor cambinol impairs MAPK signaling, inhibits inflammatory and innate immune responses and protects from septic shock."
06/01/2013 - "Going well along with its powerful anti-inflammatory activity, cambinol reduced TNF blood levels and bacteremia and improved survival in preclinical models of endotoxic shock and septic shock. "
06/01/2012 - "Vorinostat and cambinol were efficacious against WT and DoxR neuroblastoma cells in vitro. "
06/01/2012 - "Both the class III HDAC inhibitor cambinol and the class I/II HDAC inhibitor vorinostat have efficacy against SK-N-SH neuroblastoma cells, including those resistant to doxorubicin."
06/01/2012 - "In vitro efficacy of vorinostat and cambinol, alone or in combination with doxorubicin, was assessed by 2-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide calorimetric assay using both wild-type (WT) and doxorubicin-resistant (DoxR) SK-N-SH neuroblastoma cells. "
|5.||Burkitt Lymphoma (Burkitt's Lymphoma)
06/15/2011 - "The second group of SIRTi (6a-q) is characterized by some analogues of cambinol (3), a well known SIRTi active against the Burkitt lymphoma. "
04/15/2006 - "Because acetylation inactivates BCL6 and has the opposite effect on the function of p53 and other checkpoint pathways, the antitumor activity of cambinol in Burkitt lymphoma cells may be accomplished through a combined effect of BCL6 inactivation and checkpoint activation. "
04/15/2006 - "Treatment of BCL6-expressing Burkitt lymphoma cells with cambinol as a single agent induced apoptosis, which was accompanied by hyperacetylation of BCL6 and p53. "
04/15/2006 - "Cambinol was well tolerated in mice and inhibited growth of Burkitt lymphoma xenografts. "
|1.||vorinostat (suberoylanilide hydroxamic acid)
|3.||Histone Deacetylase Inhibitors
|4.||Valproic Acid (Valproate, Semisodium)
|1.||Heterologous Transplantation (Xenotransplantation)